Table 2 Treatment characteristics (as treated population)
Arm A: E-T-CMF N = 327 | Arm B: E-CMF-wD N = 317 | Arm C: E-CMF-wT N = 342 | |
|---|---|---|---|
N (%) | N (%) | N (%) | |
Number of cycles per patient | |||
1 | 1 (0.3) | 2 (0.6) | 3 (0.9) |
2 | 2 (0.6) | 2 (0.6) | 3 (0.9) |
3 | 1 (0.3) | 2 (0.6) | - |
4 | 3 (0.9) | 2 (0.6) | 3 (0.9) |
5 | 4 (1.2) | - | - |
6 | 3 (0.9) | 2 (0.6) | 6 (1.8) |
7 | 1 (0.3) | 1 (0.3) | 1 (0.3) |
8 | 6 (1.8) | 2 (0.6) | 2 (0.6) |
9 | 306 (93.6) | 2 (0.6) | 4 (1.2) |
10 | - | 2 (0.6) | - |
11 | - | 1 (0.3) | - |
12 | - | 3 (0.9) | 2 (0.6) |
13 | - | 4 (1.3) | 7 (2.0) |
14 | - | 12 (3.8) | 10 (2.9) |
15 | - | 280 (88.3) | 301 (88.0) |
Total cycles given | 2867 | 4560 | 4886 |
Median (range) | 9 (1-9) | 15 (1-15) | 15 (1-15) |
Median (range) | Median (range) | Median (range) | |
Dose intensity (DI) | |||
Epirubicin | 54 (26-58) | 54 (26-64) | 54 (30-64) |
Paclitaxel | 100 (57-105) | - | 78 (20-121) |
Cyclophosphamie | 410 (204-650) | 414 (191.5-490) | 410 (170-486) |
Methotrexate | 28 (14-44) | 28 (13.2-43) | 28 (11-43) |
Fluorouracil | 410 (204-650) | 414 (191.5-490) | 410 (170-486) |
Docetaxel | - | 34 (15.7-80) | - |
Relative dose intensity (RDI) | |||
Epirubicin | 1.0 (0.5-1.1) | 1.0 (0.5-1.2) | 1.0 (0.6-1.2) |
Paclitaxel | 1.0 (0.6-1.1) | - | 1.0 (0.3-1.5) |
Cyclophsphamide | 1.0 (0.5-1.6) | 1.0 (0.5-1.2) | 1.0 (0.4-1.2) |
Methotrexate | 1.0 (0.5-1.5) | 1.0 (0.5-1.5) | 1.0 (0.4-1.5) |
Fluorouracil | 1.0 (0.5-1.6) | 1.0 (0.5-1.2) | 1.0 (0.4-1.2) |
Docetaxel | - | 1.0 (0.5-2.3) | - |